dPCR LNA Mutation Assays

For detecting specific DNA sequence mutations related to cancer and oncogenesis

  • Duplex assay design detects mutated and wild-type sequences
  • Choice of FAM + HEX or Atto 550 + ROX fluorescent dye combinations
  • LNA-enhanced primers and probes increase assay specificity and sensitivity
  • Wet-lab tested dPCR assays available for more than 200 targets
  • Suitable for use with circulating tumor DNA, liquid biopsy, FFPE and other tissue samples
  • Intended for use with QIAcuity MasterMix

Product

ProductList_Title

ProductList_Teaser_CompareAll_Title

ProductList_Teaser_CompareAll_Description

GeneSymbols
ABL1 (4)
BRAF (9)
BTK (2)
CancerTypes
Acute Leukemias (67)
Breast Cancer (33)
Chronic Leukemia (68)
You've viewed 5 of 201 Products
Loading

Resources_Title

Available Product Catalog (2)
Instrument User Manuals (1)
Quick-Start Protocols (1)
Safety Data Sheets (1)
Application Notes (2)
Application Note: Optimized urine liquid biopsy workflow: From sample collection to cfDNA stabilization and purification, ready for digital PCR analysis
Digital PCR (dPCR) is a powerful technique that detects and quantifies ultra-rare mutations in a high background of wild-type cfDNA down to 0.1% variant allele frequency. Here, we describe end-to-end manual and automated workflows that enable accurate detection and absolute quantification of ultra-rare PIK3CA variants in cfDNA using the QIAcuity Digital PCR System.
Certificates of Analysis (1)